modern diagnostic & research centre limited IPO
About Company
The company provides reliable diagnostic tests, home specimen collection, online reports, and customized test packages for institutional customers and patients based on their specific needs.
The company operates 21 centers (18 labs, 3 diagnostic centers) across 8 states, offering diagnostic services like ultrasound, CT, MRI, X-ray, ECG, PFT, and specialized labs for heart and neuro care.
Services:
Pathology:MDRC provides a wide array of tests, including high-end molecular diagnostics, cytogenetics, and specialized panels for genetic disorders and cancer.
Radiology:The centre offers advanced imaging services such as MRI, CT scans, ultrasound, and digital X-rays, utilizing state-of-the-art equipment like a 3-Tesla MRI machine and a 128-slice CT scanner.
Home Sample Collection:MDRC offers home blood sample collection services in several cities, providing convenience for patients unable to visit the centre.
Competitive Strengths:
Experienced Promoter and Management Team
Comprehensive diagnostics provider delivering all-in-one solution at cost-effective prices
Focus on quality and customer service
Centralized information technology platform
Investment Objective
Funding Working Capital Requirement
Repayment of certain outstanding borrowings availed by the Company
General Corporate Expenses
Important Dates
Financial Performance
IPO Lot Size
Allocation Breakdown
Issue Details
Bali Nagar City landmark near Khetar Pal Hospital,
Ramesh Nagar, West Delhi
West Delhi, New Delhi, 110015
Registrar
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Modern diagnostic & research centre limited IPO is a public issue in which the company offers its equity shares to investors through the stock exchange. The IPO allows retail investors, HNIs, and institutional investors to participate.
The IPO price band of Modern diagnostic & research centre limited IPO is ₹85 to ₹90 per share, as mentioned in the issue details.
The minimum investment in Modern diagnostic & research centre limited IPO is ₹288000, based on the minimum lot size applicable for retail investors.
The lot size of Modern diagnostic & research centre limited IPO is 1600 shares per lot, and applications must be made in multiples of this lot size.
Modern diagnostic & research centre limited IPO opens on 31 Dec 2025 and closes on 2 Jan 2026, as per the announced IPO schedule.
The Modern diagnostic & research centre limited IPO subscription status shows how many times the issue has been subscribed across retail, HNI, and institutional categories during the IPO period.
The Modern diagnostic & research centre limited IPO GMP (Grey Market Premium) today is around ₹undefined, reflecting current grey market activity before listing.
Modern diagnostic & research centre limited IPO GMP is currently negative, indicating prevailing sentiment in the grey market. GMP may change daily based on demand.
A positive Modern diagnostic & research centre limited IPO GMP may suggest potential listing interest, while actual listing performance depends on subscription levels and overall market conditions.
From a retail investor perspective, Modern diagnostic & research centre limited IPO is evaluated based on pricing, lot size, subscription trends, and market sentiment. Investors should assess these factors before applying.
The Modern diagnostic & research centre limited IPO listing date is expected to be 31 Dec 2025, subject to completion of allotment and exchange procedures.
The expected listing price of Modern diagnostic & research centre limited shares depends on demand, subscription response, GMP trends, and overall market sentiment at the time of listing.
Modern diagnostic & research centre limited IPO allotment status can be checked online once the allotment process is completed using PAN, application number, or DP ID details.
Modern diagnostic & research centre limited IPO is categorized as a SME IPO based on the exchange and issue structure.
Yes, Modern diagnostic & research centre limited IPO subscription figures and GMP may change during the issue period and before listing due to market activity and investor demand.